KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$136.5 million.

  • Novavax's Cash from Investing Activities fell 52782.97% to -$136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year increase of 11267.27%. This contributed to the annual value of -$204.0 million for FY2024, which is 24696.8% down from last year.
  • As of Q3 2025, Novavax's Cash from Investing Activities stood at -$136.5 million, which was down 52782.97% from $111.1 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Cash from Investing Activities ranged from a high of $144.0 million in Q4 2024 and a low of -$372.7 million during Q2 2024
  • For the 5-year period, Novavax's Cash from Investing Activities averaged around -$18.7 million, with its median value being -$16.4 million (2021).
  • The largest annual percentage gain for Novavax's Cash from Investing Activities in the last 5 years was 168632.96% (2024), contrasted with its biggest fall of 469119.42% (2024).
  • Novavax's Cash from Investing Activities (Quarter) stood at -$16.4 million in 2021, then crashed by 34.83% to -$22.1 million in 2022, then skyrocketed by 58.86% to -$9.1 million in 2023, then soared by 1686.33% to $144.0 million in 2024, then tumbled by 194.81% to -$136.5 million in 2025.
  • Its Cash from Investing Activities was -$136.5 million in Q3 2025, compared to $111.1 million in Q2 2025 and -$73.3 million in Q1 2025.